A detailed history of Redmile Group, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 504,532 shares of RAPT stock, worth $539,849. This represents 0.07% of its overall portfolio holdings.

Number of Shares
504,532
Previous 536,682 5.99%
Holding current value
$539,849
Previous $1.64 Million 38.02%
% of portfolio
0.07%
Previous 0.11%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.76 - $3.75 $56,584 - $120,562
-32,150 Reduced 5.99%
504,532 $1.01 Million
Q2 2024

Aug 14, 2024

SELL
$2.89 - $9.38 $363,319 - $1.18 Million
-125,716 Reduced 18.98%
536,682 $1.64 Million
Q1 2024

May 15, 2024

BUY
$6.87 - $26.45 $2.03 Million - $7.82 Million
295,622 Added 80.6%
662,398 $5.95 Million
Q4 2023

Feb 14, 2024

SELL
$11.28 - $25.46 $734,813 - $1.66 Million
-65,143 Reduced 15.08%
366,776 $9.11 Million
Q2 2023

Aug 14, 2023

SELL
$16.06 - $21.61 $4.11 Million - $5.54 Million
-256,213 Reduced 37.23%
431,919 $8.08 Million
Q1 2023

May 15, 2023

SELL
$17.19 - $30.8 $1.66 Million - $2.98 Million
-96,700 Reduced 12.32%
688,132 $12.6 Million
Q3 2022

Nov 14, 2022

SELL
$17.96 - $30.46 $592,680 - $1.01 Million
-33,000 Reduced 4.04%
784,832 $18.9 Million
Q2 2022

Aug 15, 2022

BUY
$10.26 - $23.59 $709,530 - $1.63 Million
69,155 Added 9.24%
817,832 $14.9 Million
Q1 2022

May 16, 2022

BUY
$17.02 - $40.22 $12.7 Million - $30.1 Million
748,677 New
748,677 $16.5 Million

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $31.7M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.